News
Public · Published
Wells Fargo maintains Amgen at Equal-Weight, raises price target to $460 from $430
Wells Fargo maintained its Equal-Weight rating on Amgen and raised its price target to $460 from $430, a 7.0% increase. The new target was roughly in line with Amgen's Nov. 3 closing price of $461.26.
Published:
Updated:
What happened
Wells Fargo maintained its Equal-Weight rating on Amgen and raised its price target to $460 from $430, a 7.0% increase. The new target was roughly in line with Amgen’s Nov. 3 closing price of $461.26.
Confirmed
Global impact / market context
The higher target reflects a modestly better valuation view from Wells Fargo, but the unchanged rating indicates it did not upgrade its overall stance. A target near the cited share price points to little implied upside on that comparison alone, potentially limiting investor interest driven by this note.
Analyst inference
The five most recent analyst targets in the article range from $378 to $480, putting Wells Fargo’s $460 target near the upper end. That spread indicates differing views of Amgen’s value; analyst targets can influence investor expectations and, in turn, buying or selling pressure.
Analyst inference
What to watch
- Watch for Wells Fargo’s next rating or target change: an upgrade or higher target could strengthen investor expectations, while a downgrade or cut could weaken them. Analyst inference
- Compare later analyst targets with the reported $378–$480 range and Amgen’s share price; changing expectations may influence investor buying or selling, though targets are estimates. Analyst inference
- The article reports only a rating and target change, not a change to Amgen’s sales, costs, or spending; those company results would shape business performance directly. Confirmed
Evidence
- Original source link unavailable